Cvent Brings Intelligence and AI to Life Across its Platform with the Launch of CventIQ™
SAN ANTONIO--(BUSINESS WIRE)-- Cvent, an industry-leading meetings, events, and hospitality technology provider, today announced the launch of Cvent IQ ™. Cvent IQ combines powerful AI capabilities with deep industry expertise, proprietary insights and analytics, a smart platform, and intelligent infrastructure to help marketers, event planners, and hospitality professionals move faster and smarter, collaborate better, and deliver more engaging, high-return experiences. Cvent CEO Reggie Aggarwal unveiled Cvent IQ during his opening keynote address at Cvent CONNECT this week.
'CventIQ enhances every aspect of the Cvent platform, and it represents our vision for a more efficient, intelligent, and collaborative future for meetings and events,' said Reggie Aggarwal, Cvent CEO & Founder.
Intelligent capabilities to power the modern event economy
'Cvent IQ enhances every aspect of the Cvent platform, and it represents our vision for a more efficient, intelligent, and collaborative future for meetings and events,' said Aggarwal. 'By infusing advanced AI into the tools our customers already use, we're empowering them to deliver more engaging events, more efficiently, with greater returns. Our launch of Cvent IQ reflects how we're bringing trustworthy, practical AI to every corner of our platform so our customers can stay ahead of today's fast-evolving landscape while remaining focused on what truly drives impact: human connection.'
Event organizers, hosts and attendees alike will feel the power of Cvent IQ.
For event planners & marketer, sample benefits include:
Instant Session Insights: Instantly analyze audience comments to understand sentiment and gain insight into speaker performance, session content engagement, session logistics, and more.
AI-Driven Content Creation: Automatically generate compelling, on-brand content for emails, speaker bios, and event pages to streamline and scale event marketing efforts.
Personalization at Scale: Deliver personalized session and networking suggestions to attendees, enhancing engagement and overall satisfaction.
For hospitality professionals, sample benefits include:
Simplified and Accelerated Prospecting: Streamline outreach with curated planner lists and personalized emails based on hotel account insights, and attract planners with immersive AI-powered 3D room layouts.
Faster Responses to Drive Conversion: Accelerate request-for-proposal (RFP) response times with AI-generated proposals, RFP insights and response assistants.
Seamless Event Execution: Use intelligent tools, such as smart rooming lists and AI-generated event diagrams, to efficiently manage group business and bring plans to life with precision.
For attendees, sample benefits include:
Personalized Event Dashboards: Direct access to a personalized event dashboard that organizes every touchpoint, including registration, agenda, contacts, CMP credits, and on-demand content, ensures each attendee has a clear view of their unique event journey at a glance.
Effortless Session Snapshots: Real-time AI transcripts and slide captures empower attendees to effortlessly save and revisit important session content with just one tap, ensuring they capture all essential insights without distraction.
Efficient Knowledge Transfer: With AI-generated summaries, attendees receive customized highlights and actionable next steps from their event experience, including sessions attended, exhibitor booths visited, and connections made, making it easy to share key takeaways and demonstrate the event's value to colleagues and superiors.
Cvent IQ will continue to evolve with new capabilities designed to meet the dynamic needs of the modern event professional, marketer and hospitality leader. To learn more about Cvent IQ, visit the website here.
About Cvent
Cvent is a leading meetings, events, and hospitality technology provider with 5,000+ employees and 24,000+ customers worldwide as of December 31, 2024. Founded in 1999, the company delivers a comprehensive event marketing and management platform and offers a global marketplace where event professionals collaborate with venues to create engaging, impactful experiences. Cvent is headquartered in Tysons, Virginia, just outside of Washington D.C., and has additional offices around the world to support its growing global customer base. The comprehensive Cvent event marketing and management platform offers software solutions to event organizers and marketers for online event registration, venue selection, event marketing and management, virtual and onsite solutions, and attendee engagement. Cvent's suite of products automates and simplifies the event management lifecycle and maximizes the impact of in-person, virtual, and hybrid events. Hotels and venues use Cvent's supplier and venue solutions to win more group and corporate travel business through Cvent's sourcing platforms. Cvent solutions optimize the event management value chain and have enabled clients around the world to manage millions of meetings and events. For more information, please visit Cvent.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
Hamilton Spectator
10 hours ago
- Hamilton Spectator
Jetoptera Executes FETT for FTC-250 at Paris Air Show 2025
PARIS, June 21, 2025 (GLOBE NEWSWIRE) — On the occasion of Jetoptera's debut at the Paris Air Show 2025, we are proud to announce the successful completion of the first test of the engine that will power the J-500, the 500-lb VTOL cargo unmanned aircraft system Jetoptera is developing in collaboration with Eanan Al Samma, for the United Arab Emirates (UAE) market. The First Engine To Test (FETT) was evaluated at the VAN DER LEE Turbo Systems facilities in Zaandam, The Netherlands. The 250 kW turbocompressor, that is the heart of the Fluidic Propulsive System™, is a two-shaft engine using a free turbine that is mechanically coupled to a two-stage axial compressor designed to produce the appropriate flow rates and pressure ratios required by the FPS™. 'The FETT demonstrated a very smooth startup and operability when operated in a turbofan mode. The engine was instrumented in this configuration, to monitor pressure and temperature as well as thrust produced. The next step includes the performance mapping of the turbocompressor, followed by the integration with the FPS™ onto the J-500 airframe,' said Dr Andrei Evulet, CEO/CTO of Jetoptera, Inc. The J-500 prototype is developed specifically for the UAE and MENA market and will be uniquely enabled by the FPS™ to perform unmanned cargo missions with VTOL and unmatched speed, low noise, and reliability thanks to the patented propulsion system. The modularity of the FTC-250 system allows its components to operate in turbojet, turbofan and FPS™ modes. Jetoptera and Eanan Al Samma thank Parametric Solutions, Inc. and VAN DER LEE Turbo Systems for their critical support in the design and manufacturing of the unique FTC-250 architecture in record time. For information about this press release please contact Todd Newton todd@ Jetoptera, Inc. Facebook: LinkedIn: A photo accompanying this announcement is available at
Business Wire
18 hours ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
